DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Lars Jorgensen - 3 Wegovy - 1 Hollie Adams - 1 Biden - 1 it's - 1 Novo - 1 Lars Fruergaard Jørgensen - 1 Ozempic - 1
Top related locs:
London Britain Novo Washington , U.S Tuscany Venice Oslo Norway
Top related orgs:
Novo Nordisk - 1 Specialty Pharmacy - 1 Centers - 1 Medicare - 1 Medicaid Services - 1 Health - 1 Education - 1 Labor - 1

Search resuls for: "Lars Jorgensen"


5 mentions found


☆ Healthy Returns: Weight loss drug Wegovy could face Medicare price negotiations next
  + stars: | 2024-09-24 | by ( Annika Kim Constantino Ashley Capoot | Annika Kim Constantino | Ashley Capoot | ) www.cnbc.com   time to read: +5 min
Wegovy, the blockbuster weight loss treatment from Novo Nordisk , tops the list of drugs that could soon become part of the second round of price negotiations between manufacturers and Medicare. The Biden administration last month announced new negotiated prices for the first 10 Medicare Part D drugs selected for the talks. He also pushed back on Medicare price negotiations when asked about the potential selection of Wegovy and Ozempic, calling the talks "price-setting" that will have negative consequences for drug innovation. Medicare Part D doesn't cover weight loss treatments unless they are approved and prescribed for another health condition. We'll be following the next round of Medicare drug price negotiations closely, so stay tuned for our coverage.
Persons: Wegovy, Hollie Adams, Biden, it's, Novo, Lars Fruergaard Jørgensen, Lars Jorgensen, Ozempic, Piroschka Van De Wouw, Jørgensen, Semaglutide, We'll, Annika, annikakim.constantino Organizations: Novo Nordisk, Reuters, Specialty Pharmacy, Centers, Medicare, Medicaid Services, Health, Education, Labor, Capitol, CMS, Wall Street, GSK, Astellas Pharma, Epic Systems Locations: London, Britain, Novo, Washington , U.S
☆ ‘Lift’ Review: Thin as Thieves
  + stars: | 2024-01-11 | by ( Robert Daniels | ) www.nytimes.com   time to read: +1 min
Kevin Hart plays Cyrus, a master thief, in the undercooked heist flick, “Lift,” directed by F. Gary Gray. Beyond the windfall Jorgensen will get from shorting water utility stocks, it’s unclear what he gains from this elaborate ruse. An Interpol agent, Abby (Gugu Mbatha-Raw), enlists Cyrus to steal the passenger plane carrying the gold bars before any damage can be done. Although Abby and Cyrus are old flames, the film doesn’t pick up any romantic steam, either, thanks to what passes for banter. “I was looking at the questions that weren’t being asked,” Cyrus tells Abby.
Persons: Kevin Hart, Cyrus, ”, Gary Gray, Daniel Kunka, Lars Jorgensen, Jean Reno, Jorgensen, Abby, Gugu, “, weren’t, ” Cyrus Organizations: Interpol Locations: Tuscany, Venice
☆ The obesity drug boom is just getting started: podcast
  + stars: | 2023-09-05 | by ( Aimee Donnellan | ) www.reuters.com   time to read: +1 min
A 0.25 mg injection pen of Novo Nordisk’s weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration Acquire Licensing RightsLONDON, Sept 5 (Reuters Breakingviews) - Over 1 bln people are obese, the WHO reckons. Denmark’s Novo Nordisk is ahead of the pharma pack with its Wegovy weight-loss drug. Listen to the podcastFollow @aimeedonnellan on XSubscribe to Breakingviews’ podcasts, Viewsroom and The Exchange. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.
Persons: Victoria Klesty, Lars Jorgensen, Oliver Taslic Organizations: REUTERS, Reuters, WHO, Denmark’s, Denmark’s Novo Nordisk, pharma, Thomson Locations: Oslo, Norway, Victoria, Denmark’s Novo
☆ Europe will lose out on medical innovation if draft EU reforms pass -Novo Nordisk CEO
  + stars: | 2023-03-02 | by ( Maggie Fick | ) www.reuters.com   time to read: +3 min
LONDON, March 2 (Reuters) - Europe will lose out to countries like the U.S. and Japan on new medical research, trials and treatments unless draft rules reforming the European pharmaceutical landscape change, the CEO of Danish drugmaker Novo Nordisk (NOVOb.CO) warned on Thursday. It says drugs need to reach patients more quickly and in all European nations. Novo's Lars Jorgensen lamented that without changes to the current draft, his company would be forced to research, test and bring products in its pipeline to market in the United States and elsewhere, instead of in Europe. A lose, lose, lose," he said in an interview. The Commission's current draft was leaked in Brussels last month and will likely change even before debate in the European parliament and among governments.
☆ Looming obesity drug rivalry not a concern for Novo CEO
  + stars: | 2022-11-15 | by ( Natalie Grover Maggie Fick | Natalie Grover | Maggie Fick | ) www.reuters.com   time to read: +4 min
The main active ingredient in Ozempic is semaglutide, which is also the key ingredient in Novo's obesity drug Wegovy. Several less efficacious obesity drugs from multiple drugmakers have previously been approved, but bungled launches and serious side effects led to tepid sales and even some market withdrawals. Novo faces looming competition from Eli Lilly (LLY.N), whose weekly injection Mounjaro won U.S. approval for type 2 diabetes in May and is under fast-track review as a weight-loss drug. Amgen (AMGN.O) also has an early-stage, once-monthly obesity drug that is being keenly watched. Elon Musk, the world's richest person and now Twitter owner, has offered his own endorsement of the weight-loss benefits of semaglutide on the social media website.
0 next >>
Total: 5